Document is current

Article History

Received: 11 June 2024

Accepted: 11 September 2024

First Online: 26 September 2024

Declarations

:

: The study protocol was reviewed and approved by the local ethics committee of the Friedrich-Alexander University of Erlangen-Nürnberg. The study was performed according to the principles of Good Clinical Practice.

: Local ethics committee of the FAU Erlangen-Nürnberg.

: <i>RT</i> received honoraria and personal lecture fees from Eisai, Desitin, Roche, Sanofi, and Biogen. <i>JJ</i> received compensation for advisory boards and funding for travel or speaker honoraria from Avexis/Novartis, Biogen, PTC, Pfizer, Roche, Santhera Pharmaceuticals and Sarepta Therapeutics. <i>KV</i> reported personal fees from Biogen, Novartis, Santhera and ITF Pharma. <i>AH</i> received honoraria for lectures and participation at advisory boards from Roche, Novartis, and Biogen. <i>SI</i> received honoraria and lecture fees from Novartis and Roche. CK has received compensation for advisory boards and speaker honoraria from Biogen, Roche, Pfizer, Novartis, and Santhera. <i>AP</i> reports research grants from Novartis, Biogen, and Roche. <i>MvdH</i> has been a member of the scientific advisory boards for Avexis, Biogen, Novartis, Pfizer, Roche and received travel expenses and lecture fees from Avexis, Novartis, Pfizer and Roche. <i>WMF</i> reported compensation for advisory boards and speaker honoraria Novartis, Roche, Biogen, PTC Therapeutics, Sarepta, Sanofi and Italfarmaco. No other disclosures were reported.